Basic Information
| LncRNA/CircRNA Name | MALAT1 |
| Synonyms | NA |
| Region | GRCh38_11:65497688-65506516 |
| Ensemble | ENSG00000251562 |
| Refseq | NR_002819 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | qRT-PCR , Luciferase reporter assay , Western blot , in vitro knockdown etc. |
| Sample | human breast cancer cell lines (MDA-MB231, MDA-MB436, SKBR3, MCF7, and T47D) and viral packaging 293T cells |
| Expression Pattern | up-regulated |
| Function Description | MALAT1 was overexpressed in breast cancer tissues and breast cancer cells. Knockdown of MALAT1 reduced cell proliferation and invasion by arresting cells at the G0/G1 phase. Ectopic overexpression of EEF1A1 reversed the altered tumor phenotypes induced by MALAT1 shRNA treatment. These data suggest an epigenetic mechanism by which MALAT1 lncRNA facilitates a pro-metastatic phenotype in breast cancer by trans-regulating EEF1A1. |
| Pubmed ID | 31105998 |
| Year | 2019 |
| Title | Genome-wide target interactome profiling reveals a novel?EEF1A1?epigenetic pathway for oncogenic lncRNA?MALAT1?in breast cancer |
External Links
| Links for MALAT1 | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |